Abstract
The cornea maintains avascularity by balancing angiogenic factors and anti-angiogenic agents. Stress on the cornea can disrupt this delicate equilibrium resulting in angiogenesis. Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a humanized monoclonal antibody which binds to all isoforms of vascular endothelial growth factor (VEGF)-A, thereby inhibiting angiogenesis. Recent studies have explored the role of bevacizumab in treating corneal neovascularization and ocular surface disease. Animal and human studies using both subconjunctival and topical bevacizumab reveal a reduction in corneal neovascularization. Evidence suggests that topical bevacizumab is safe and may be effective in the treatment of corneal neovascularization. Case studies suggest that bevacizumab may be useful in limiting the recurrence of corneal neovascularization when combined with corneal transplant surgery. A few reports have assessed the role of bevacizumab in pterygium surgery as well. These preliminary studies suggest that the use of subconjunctival bevacizumab may be beneficial in the treatment of pterygia but its benefit has not been defined. The role of bevacizumab in corneal and ocular surface disease continues to evolve.
Keywords: Antivascular endothelial growth factor, bevacizumab, cornea, pterygium, corneal neovascularization, infection, degeneration, inflammation, surface disease, lipid keratopathy
Current Drug Therapy
Title:Anti-VEGF Treatment of Anterior Segment Disorders of the Eye
Volume: 7 Issue: 2
Author(s): Saiyid A. Hasan
Affiliation:
Keywords: Antivascular endothelial growth factor, bevacizumab, cornea, pterygium, corneal neovascularization, infection, degeneration, inflammation, surface disease, lipid keratopathy
Abstract: The cornea maintains avascularity by balancing angiogenic factors and anti-angiogenic agents. Stress on the cornea can disrupt this delicate equilibrium resulting in angiogenesis. Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a humanized monoclonal antibody which binds to all isoforms of vascular endothelial growth factor (VEGF)-A, thereby inhibiting angiogenesis. Recent studies have explored the role of bevacizumab in treating corneal neovascularization and ocular surface disease. Animal and human studies using both subconjunctival and topical bevacizumab reveal a reduction in corneal neovascularization. Evidence suggests that topical bevacizumab is safe and may be effective in the treatment of corneal neovascularization. Case studies suggest that bevacizumab may be useful in limiting the recurrence of corneal neovascularization when combined with corneal transplant surgery. A few reports have assessed the role of bevacizumab in pterygium surgery as well. These preliminary studies suggest that the use of subconjunctival bevacizumab may be beneficial in the treatment of pterygia but its benefit has not been defined. The role of bevacizumab in corneal and ocular surface disease continues to evolve.
Export Options
About this article
Cite this article as:
A. Hasan Saiyid, Anti-VEGF Treatment of Anterior Segment Disorders of the Eye, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800676011
DOI https://dx.doi.org/10.2174/157488512800676011 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Melanocortins and their Receptors and Antagonists
Current Drug Targets Update On Emerging Antivirals For The Management Of Herpes Simplex Virus Infections: A Patenting Perspective
Recent Patents on Anti-Infective Drug Discovery Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Current Developments in the Synthesis and Biological Activity of Aza-C-Nucleosides:Immucillins and Related Compounds
Current Medicinal Chemistry Brain Tumor Detection Using Machine Learning and Deep Learning: A Review
Current Medical Imaging Sonic Hedgehog, the Penis and Erectile Dysfunction: A Review of Sonic Hedgehog Signaling in the Penis
Current Pharmaceutical Design Antimutagenic Activity of Lutein –An Oxycarotenoid Present in the Macula and its Inhibition of Cytochrome P 450 Enzymes in vitro
Drug Metabolism Letters Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration
Current Drug Therapy Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry